LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Accueil・Liste d'Actions・Puma Biotechnology Inc

Puma Biotechnology Inc

Fermé

SecteurSoins de santé

6.79 0.3

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.6

Max

6.82

Chiffres clés
By Trading Economics
Revenu	-16M -3.8M
Ventes	-31M 45M
P/E Moyenne du Secteur	14.188 49.701
BPA	-0.04
Marge bénéficiaire	-8.375
Employés	179
EBITDA	-28M -1.3M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	-26.58% downside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-37M 347M
Ouverture précédente	6.49
Clôture précédente	6.79

Sentiment de l'Actualité

By Acuity

50%

174 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

3.07 / 3.075 Support & Résistance

Puma Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 mai 2026, 20:36 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Résultats

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Résultats

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mai 2026, 22:02 UTC

Résultats

ZTO Express (Cayman): Di Xu to Resign From Board

19 mai 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mai 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mai 2026, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mai 2026, 21:37 UTC

Résultats

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mai 2026, 21:01 UTC

Résultats

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mai 2026, 20:58 UTC

Résultats

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mai 2026, 20:46 UTC

Actions en Tendance

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mai 2026, 20:34 UTC

Résultats

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries 4Q EPS 5c >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries 4Q Sales $1.4B >JHX

19 mai 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mai 2026, 20:03 UTC

Acquisitions, Fusions, Rachats

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mai 2026, 20:03 UTC

Acquisitions, Fusions, Rachats

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mai 2026, 20:02 UTC

Acquisitions, Fusions, Rachats

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mai 2026, 20:02 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparaison

Variation de prix

Puma Biotechnology Inc prévision

Objectif de Prix

By TipRanks

-26.58% baisse

Prévisions sur 12 Mois

Moyen 5 USD -26.58%

Haut 5 USD

Bas 5 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

3.07 / 3.075Support & Résistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

174 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.